School of Medicine Research Teams Led by Zhang Xiaokun and Su Ying published in subsidiary of Cell
Posted: 2014-04-05 Visits: 191
Chen Liqun, a Ph.D student from the School of Medicine, published results of his groundbreaking research of an anti-cancer drug molecule in Chemistry & Biology (a subsidiary of Cell) as the first author, with Prof. Zhang Xiaokun and Prof. Su Ying as corresponding authors. The article discusses Liqun’s finding that Retinoid X receptor-alpha (RXRα), an intriguing and unique drug target, can serve as an intracellular target mediating the anticancer effects of certain nonsteroidal anti-inflammatory drugs (NSAIDs). The research was funded by research teams led by Prof. Zhang and Prof. Su, who are members of China’s “Thousand Talent Program”.
Back in 2010, Prof. Zhang and his team published an article on Cancer Cell, also a top journal. The researchers found that the non-steroidal anti-inflammatory drug Sulindac could eliminate certain factors, in turn destroying cancer. Based on that finding, Prof. Zhang’s team and Prof. Su’s team worked with the research team led by Prof. Huang Peiqiang from College of Chemistry and Dr. Robert Liddington’s laboratory at the Sanford-Burnham Medical Research Institute in La Jolla, California, to further optimize K-8003. Their work represents another major breakthrough in cross-disciplinary and international cooperation since the publication of a research paper in European Journal of Medicinal Chemistry by Prof. Zhang, Prof. Su and Prof. Huang in 2013. It is also an extraordinary step forward in the process of Xiamen University’s independently developed anti-cancer drugs.
The full article can be found here:
http://www.cell.com/chemistry-biology/abstract/S1074-5521(14)00077-5
